Connect your AI

Sutro Biopharma STRO Earnings yield

Earnings yield at other companies

PfizerPFE

6.8%—

Gilead SciencesGILD

5.3%+1.1pp

RegenxbioRGNX

-67.1%+73.5pp

Nuvectis Pharma, Inc.NVCT

-13.3%+13.4pp

XencorXNCR

-19.5%-4.5pp

AnaptysBio, Inc.ANAB

-9.9%-2.8pp

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Calculated from Sutro Biopharma’s reported figures.

net income/market cap=-37.2%

Based on trailing twelve months.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's earnings yield?: Sutro Biopharma (STRO) reported earnings yield of -37.2% in Q1 2026.
How has Sutro Biopharma's earnings yield changed year-over-year?: Sutro Biopharma's earnings yield increased by 91.7% year-over-year, from -449.9% to -37.2%.
What is the long-term trend for Sutro Biopharma's earnings yield?: Over 4 years (2020 to 2025), Sutro Biopharma's earnings yield has grown at a 179.0% compound annual growth rate (CAGR), from -3.2% to -193.9%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.